GRTS: Gritstone Bio Net earnings per share (EPS TTM)

Gritstone bio (GRTS) - corporate logo

The implementation of AI and robotic RNA synthesis optimizes vaccine development at Gritstone bio, Inc. (GRTS). The EPS trend over the last 12 months demonstrates current dynamics, where -1.16 reflects the metric's baseline. Risk mitigation is provided by a balance of oncology drugs and antivirals, although the high cost of personalized treatment and clinical trial uncertainty create financial challenges.

GRTS Gritstone bio, Inc. Net earnings per share for the last 12 months (07/04/2022 - 11/02/2024)

Summary analytical data breakdowns for Gritstone bio, Inc. (GRTS)

- share price and expert price forecast:
Fundamental valuation:GRTS - gritstonebio.com
Flagship merchandise of Gritstone Bio

Investors must filter out issuers with deteriorating yields to minimize capital losses. The operational resilience of Gritstone bio, Inc. (GRTS) depends on the outcomes of mRNA vaccine clinical trials amid patent battles with pharma behemoths. By analyzing the EPS trend over the last 12 months, we assess the rolling net income allocated per share. The current value of -1.16 reflects the real fundamental efficiency of the business. The dynamics of this metric determine the reliability of investments in the high-risk biotech sector.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)